Since the introduction of PD-1/PD-L1 blockers in 2015, patients without molecular therapeutic targets now receive treatment with one of the immune checkpoint therapies in the first-line setting, especially for squamous NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.